Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of 1-dose vs 2-dose Zostavax in Elderly
NCT00561080Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2007
- Primary completion
- Jun 2009
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, randomised, open-label trial of varicella virus vaccine live in herpes zoster (HZ) (3 arms), sponsored by Merck & Co. Primary endpoint: Geometric Mean Titer of Varicella Zoster Virus Antibodies. Started Oct 2007; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT00561080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00561080.